FIG. 4.

Basal expression of MMP9 and Runx2 in nonmetastatic and bone metastatic cancer cells. (A) Total RNA from bone metastatic breast cancer cells (MDA-MB-231) and prostate cells (PC3), as well as from nonmetastatic breast (MCF-7) and prostate (LNCaP) tumor cells, was utilized to examine endogenous MMP9 mRNA levels by RT-QPCR analysis. Data were normalized to the GAPDH signal. (B) Whole-cell lysates from cancer cells were utilized to detect Runx2 protein with a monoclonal antibody by Western blotting. cdk2 protein levels are shown as an internal loading control.